Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/flgastro-2020-101531 http://scihub22266oqcxt.onion/10.1136/flgastro-2020-101531 34249317!8231424!34249317     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\34249317.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Frontline+Gastroenterol 2021 ; 12 (4): 316-321 Nephropedia Template TP {{tp|p=34249317|t=2021. Implications of recurrent SARS-CoV-2 outbreaks for IBD management |pdf=|usr=}}{{34249317}} gab.com Text Implications of recurrent SARS-CoV-2 outbreaks for IBD management JO: Frontline Gastroenterol http://www.kidney.de/pget.php?&tw=1&pmid=34249317 #FOAvip The initial phases of the global SARS-CoV2 pandemic had significant implications for the management of patients with inflammatory bowel disease (IBD). This impact is likely to be sustained and far-reaching across all models of care. Initial questions about the risk of SARS-CoV2 infection, and COVID-19 complications, in patients taking maintenance anti-TNFs, JAK inhibitors and other immune modulators have preliminary data. Current models for SARS-CoV-2 transmission predict intermittent outbreaks until 2022, which could disrupt clinical care and negatively affect outcomes for many patients across the globe. This review summarises changes in IBD clinical practice that will be required during the 'post-peak' phase of viral pandemics. Twit Text FOAVip Implications of recurrent SARS-CoV-2 outbreaks for IBD management ????Frontline Gastroenterol http://www.kidney.de/pget.php?&tw=1&pmid=34249317 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34249317 #FOAvip English Wikipedia <ref>{{Cite pmid|34249317}}</ref> Implications of recurrent SARS-CoV-2 outbreaks for IBD management #MMPMID34249317 Segal JP; Moss AC Frontline Gastroenterol 2021[]; 12 (4): 316-321 PMID34249317show ga The initial phases of the global SARS-CoV2 pandemic had significant implications for the management of patients with inflammatory bowel disease (IBD). This impact is likely to be sustained and far-reaching across all models of care. Initial questions about the risk of SARS-CoV2 infection, and COVID-19 complications, in patients taking maintenance anti-TNFs, JAK inhibitors and other immune modulators have preliminary data. Current models for SARS-CoV-2 transmission predict intermittent outbreaks until 2022, which could disrupt clinical care and negatively affect outcomes for many patients across the globe. This review summarises changes in IBD clinical practice that will be required during the 'post-peak' phase of viral pandemics. äImplications of recurrent SARS-CoV-2 outbreaks for IBD management (epmc).pdf DeepDyve Pubget Overpricing